BAY3375968
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BAY3375968, covering 2026-04-21 to 2026-04-21. Get the full timeline:
Most recent: Clinical Trial Update: A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors [Phase 1]